Get started
Work

A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Year: 2022
Type: conference-abstract
DOI: 10.1200/jco.2022.40.16_suppl.tps5101
Authors: Daniel Costin Danila, David Michael Waterhouse, Leonard Joseph Appleman, David William Pook, Nobuaki Matsubara, Tanya B. Dorff, Jae-Lyun Lee, Andrew J. Armstrong, Miso Kim, Lisa Horvath, Christopher Joseph Sumey, Freda Cooner, Mark Salvati, Julia Stieglmaier, William Kevin Kelly
Institutions: Memorial Sloan Kettering Cancer Center, Oncology Hematology Care, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Monash Health, National Cancer Center Hospital East, City Of Hope National Medical Center, Asan Medical Center, University of Ulsan, Duke University, Duke Medical Center, Duke Cancer Institute, Seoul National University, Seoul National University Hospital, Chris O’Brien Lifehouse, Sanford Health, Amgen (United States), Amgen (Germany), Thomas Jefferson University, Sidney Kimmel Cancer Center
Language: English
Field: Medicine
Open Access status: closed
Funder: Amgen
OpenAlex ID: W4281611909
Cites:
Cited by: 8
Related to: 10